Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: Explore the inspiring stories of the Fierce 50
Revlimid
Pharma
BMS aims for staggering 25 label expansions in the coming years
Bristol Myers Squibb bets its pipeline can more than withstand the pressure from the Inflation Reduction Act and a trio of weighty patent losses.
Fraiser Kansteiner
Sep 15, 2023 12:04pm
BMS again cuts staff after disappointing 2Q earnings
Aug 11, 2023 2:41pm
BMS, BeiGene end legacy Celgene deal years after China ban
Aug 3, 2023 10:25am
With Revlimid sales down, BMS slashes 2023 revenue projection
Jul 27, 2023 11:43am
BMS, generics companies face new suit over Revlimid 'monopoly'
Nov 22, 2022 11:38am
To fix IRA loophole, lawmaker targets drug launch prices
Nov 3, 2022 11:36am
